a thorough understanding of the specific requirements.

United States

In the U.S., the FDA defines combination products under the Federal Food, Drug, and Cosmetic Act (FDCA). According to Section 503(g) of the FDCA, combination products can be classified primarily as either a drug, device, or biologic. The Office of Combination Products (OCP) is responsible for the assignment of combination products to the appropriate regulatory pathway. The regulatory classification will dictate the applicable processes and requirements, including:

• Pre-market approval (PMA) for Class III devices
• New Drug Application (NDA) for drugs
• Biologics License Application (BLA) for biologics

European Union

In the EU, combination products are governed by several regulations including the Medical Devices Regulation (EU) 2017/745 and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746. The classification criteria take into account the primary mode of action of the product—whether it is a medicinal product or a device. The European Medicines Agency collaborates with competent authorities in member states to evaluate combination products. The distinct regulatory frameworks necessitate adherence to the respective documentation requirements, including Clinical Investigations and Technical Documentation.

United Kingdom

Post-Brexit, the UK follows its regulatory framework guided by the UK Medical Devices Regulations 2002 (as amended). The MHRA is the agency responsible for regulating combination products, and similar principles apply for establishing whether a product is classified as a medical device or medicinal product. Manufacturers need to provide adequate Justification and documentation for their intended classifications.

Documentation

Effective documentation is essential for the approval of drug–device combination products. The documentation must provide sufficient evidence that the product meets the regulatory requirements laid out by the respective authorities. Key components of documentation include the following:

Quality Technical File / Dossier

A comprehensive Quality Technical File (QTF) or Quality Dossier is essential. It should include:

• Product description
• Intended use and indications
• Device design and manufacturing information
• Information on the drug substance and excipients
• Labeling and instructions for use
• Risk management file according to ISO 14971

Clinical Evaluation

Clinical evidence is critical in supporting the safety and efficacy of combination products. The evidence should be compliant with ICH E6 Guidelines for Good Clinical Practice (GCP). Clinical studies should be designed to demonstrate the therapeutic effect in accordance with the primary mode of action (drug or device). The assessment of safety must span both the drug and device components, providing justification for their combined use to address the medical need.

Post-Market Surveillance Plan

A robust post-market surveillance strategy is vital. Global pharmacovigilance requirements dictate that the manufacturer must have a plan in place to monitor the safety of both the medicinal and device aspects post-approval. The pharmacovigilance system should capture adverse event data efficiently and comply with regulatory reporting timelines as per ICH E2E guidelines and respective authority requirements.

Review/Approval Flow

The review and approval process for combination products often involves various stages that differ based on local regulations and product classification.

United States Process Flow

1. Submission of a 510(k), PMA, or NDA: Depending on the product classification, the manufacturer must submit the appropriate application to the FDA.
2. Office of Combination Products Assignment: The OCP assigns the application to the relevant FDA center for review.
3. Review Process: The designated FDA center conducts a comprehensive evaluation, including pre-market inspections of manufacturing facilities.
4. Approval and Post-Market Monitoring: Once approved, manufacturers must adhere to post-market surveillance obligations as stipulated.

European Union Process Flow

1. Device classification: Determine the primary mode of action of the combination product.
2. Notified Body assessment: For medical device classification, the application is submitted to a Notified Body for evaluation.
3. Compliance with the MDR and IVDR: Manufacturers must comply with Medical or In Vitro Device Regulations.
4. CE Marking and Market Access: Following successful examination and audits, products are granted CE marking, permitting access to the EU market.

UK Process Flow

1. Classification and submission: Classify the product according to the UK regulated criteria.
2. MHRA validation: Submission is evaluated by the MHRA, which may involve consultations with independent experts.
3. Approval and post-market compliance: Post-approval, adherence to post-market surveillance strategies is necessary.

Common Deficiencies

During the regulatory review process, several common deficiencies are frequently identified. Understanding these can assist regulatory affairs professionals in proactively addressing potential issues:

• Lack of Clarity in the Intended Use: Ensure that intended use and indications are clearly defined across all documents to prevent confusion.
• Inadequate Clinical Evidence: Clinical study designs must be robust and should align with the proposed mechanism of action.
• Insufficient Technical Documentation: All aspects of the device and drug components must be sufficiently documented, particularly risk management and quality assurance.
• Poor Post-Market Surveillance Strategies: Ineffective monitoring systems can lead to compliance issues. Thorough systems must be established for ongoing safety reporting.

Regulatory Affairs-Specific Decision Points

Several critical decision points arise during the development of drug–device combination products, especially regarding regulatory submissions:

When to File as a Variation vs. New Application

Determining whether to file a variation or a new application hinges on the extent of changes made to the product. Key considerations include:

• The depth of modifications: Minor changes that impact product quality or indications may qualify for a variation.
• Regulatory authorities’ definitions: Review the specific criteria defined by the FDA, EMA, or MHRA to ascertain the necessary filing approach.

Justifying Bridging Data

Bridging data may be required when evidence from a related product or population is used to support a new application. Consider:

• The relevance of previous data: Evidence must clearly demonstrate similarity or supportive evidence for safety and efficacy.
• Regulatory authority expectations: Consult applicable guidance documents to ensure compliance with expectations for the use of bridging data.

Conclusion

Understanding the complexities of regulating drug–device combination products is essential for regulatory affairs professionals operating within the pharmaceutical and biotech landscape. By adhering to the specific guidelines laid out by the FDA, EMA, and MHRA, and recognizing key challenges and decision points, professionals can navigate the regulatory landscape more effectively. The importance of robust documentation, clear intended use, adequate clinical evaluation, and thorough post-market monitoring cannot be overstated, and proactive measures can help mitigate common deficiencies that may impede product approval.

For comprehensive information on regulatory guidelines, refer to the official sources such as FDA’s Combination Products overview, EMA’s Combination Products guidelines, or the MHRA’s resources for combination products.